Effects of secukinumab injection: A Synthesis of Findings from 19 Studies

  1. Home
  2. Effects of secukinumab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of secukinumab injection: A Synthesis of Findings from 19 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of secukinumab injection: A Synthesis of Findings from 19 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown promising results in treating various inflammatory diseases. 6 12 8 18 2 5 9 These studies suggest that secukinumab may be effective for treating moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and noninfectious uveitis. 6 12 8 18 2 5 9 Additionally, research suggests that secukinumab may be more effective and faster in clearing skin than ustekinumab, another biologic treatment for psoriasis, particularly in Asian patients. 5 Furthermore, secukinumab has shown potential benefits in treating severe ABCA12 deficiency-related ichthyosis in children. 14 Secukinumab has also demonstrated a positive effect on cognitive impairment in a rat model of sepsis by reducing oxidative stress and neuronal apoptosis. 3

Benefits and Risks

Benefit Summary

Secukinumab shows promising results for treating various inflammatory conditions, including moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and noninfectious uveitis. 6 12 8 18 2 5 9 Research indicates that secukinumab might be more effective and faster at clearing skin than ustekinumab, especially for Asian patients. 5 Secukinumab has also demonstrated effectiveness in treating severe ABCA12 deficiency-related ichthyosis in children. 14 Moreover, secukinumab has shown potential benefits in improving cognitive impairment in a rat model of sepsis by reducing oxidative stress and neuronal apoptosis. 3

Risk Summary

While generally considered safe, secukinumab may cause side effects such as injection site reactions, oral candidiasis, and flu-like symptoms. 16 13 In rare cases, secukinumab may also trigger new skin conditions like psoriasis or atopic dermatitis. Additionally, some patients might not respond to anti-IL-17A therapies like secukinumab. 9

Comparison Across Studies

Commonalities Across Studies

Several studies consistently demonstrate the effectiveness of secukinumab in treating various inflammatory diseases. 6 12 8 18 2 5 9 Research also consistently suggests that secukinumab is generally safe. 6 15 8 13

Differences Across Studies

The dosage and administration methods of secukinumab vary across studies. 15 8 Additionally, the targeted diseases and patient populations differ among these studies. 6 12 8 18 2 5 9 Therefore, directly comparing results across studies can be challenging. It's important to remember that secukinumab's effectiveness may vary depending on the individual patient's condition and disease. 7

Consistency and Contradictions in Findings

While secukinumab demonstrates effectiveness across various inflammatory diseases, some patients might not respond to anti-IL-17A therapies like secukinumab. 9 The effectiveness of secukinumab can vary based on individual patient factors and the specific disease being treated. 7 Secukinumab is generally considered safe, but potential side effects such as injection site reactions, oral candidiasis, and flu-like symptoms can occur. 16 13 Additionally, new skin conditions like psoriasis or atopic dermatitis may develop after secukinumab administration in rare cases.

Considerations for Real-World Application

While secukinumab holds potential for treating various inflammatory diseases, its effects and side effects can vary depending on the individual patient and their condition. 7 It's crucial to consult with a healthcare professional before considering secukinumab, thoroughly understand the risks and benefits, and make informed decisions about the most appropriate treatment options. 7

Limitations of Current Research

Further research is necessary to evaluate the long-term safety and effectiveness of secukinumab. 18 Additional studies are also needed to understand how secukinumab's effects vary based on individual patient factors and the specific disease being treated. 7

Future Research Directions

Large-scale, long-term follow-up studies are needed to assess the long-term safety and effectiveness of secukinumab. 18 Further research is necessary to understand how secukinumab's effects differ based on individual patient factors and the specific disease being treated. 7 Research is also required to determine how secukinumab affects patients who do not respond to anti-IL-17A therapies. 9

Conclusion

Secukinumab holds potential as a treatment option for various inflammatory diseases. However, consulting with a healthcare professional, carefully considering risks and benefits, and selecting appropriate treatment options based on individual needs are essential. 7 Further research is crucial to evaluate the long-term safety and effectiveness of secukinumab, and to understand how its effects vary depending on individual patient factors and specific diseases. 18 7 9

Literature analysis of 19 papers
Positive Content
17
Neutral Content
0
Negative Content
2
Article Type
8
1
1
1
18
1.

Dose effects of secobarbital in a Sternberg memory scanning task.

Author: WilliamsH L, RundellO H, SmithL T

Slowed reaction time

This study investigated the effects of secobarbital, a barbiturate, on reaction times in a memory-scanning task in human volunteers. Both doses of secobarbital significantly slowed reaction time. The discriminability of the probe stimulus interacted with the barbiturate, producing a hyperadditive effect on reaction time, only at the high dose.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

2.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.

Author: GenoveseMark C, DurezPatrick, RichardsHanno B, SupronikJerzy, DokoupilovaEva, MazurovVadim, AelionJacob A, LeeSang-Heon, CoddingChristine E, KellnerHerbert, IkawaTakashi, HugotSophie, MpofuShephard

Reduced CRP
Infections

Secukinumab did not achieve the primary efficacy endpoint of ACR20 response at week 16 but showed clinically relevant decreases in disease activity score and CRP levels compared to placebo.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Secukinumab alleviates cognitive impairment by attenuating oxidative stress and neuronal apoptosis via the IL-17RA/AKT/ERK1/2 pathway in a rat model of sepsis.

Author: GaoJiamin, WangYiduo, MaSenlin, XuSiyuan, ChenMingquan

Alleviated cognitive impairment
Septic-associated encephalopathy

Secukinumab, an IL-17A inhibitor, could potentially alleviate cognitive impairment in a rat model of sepsis. This study aims to investigate the effects of secukinumab and explore its underlying molecular mechanism.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.

Author: LeeMin-Geol, HuangYu-Huei, LeeJoo-Heung, LeeSeung-Chul, KimTae-Gyun, AwDerrick Chen-Wee, BaoWeibin, DeeCathleen Michelle A, GuanaAdriana, TsaiTsen-Fang

Psoriasis treatment

This study examined the effectiveness of secukinumab, a drug used to treat psoriasis, in Asian patients with moderate to severe psoriasis. The study found that secukinumab was highly effective and well-tolerated in this population.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.

Author: SticherlingM, MrowietzU, AugustinM, ThaçiD, MelzerN, HentschkeC, KneidlJ, SiederC, ReichK

Psoriasis treatment
Psoriatic arthritis treatment

This study compared secukinumab with fumaric acid esters (FAEs) in a randomized controlled trial. Secukinumab demonstrated superior efficacy to FAEs in patients with psoriasis over a 24-week period.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

7.

Japanese guidance for use of biologics for psoriasis (the 2019 version).

Author: SaekiHidehisa, TeruiTadashi, MoritaAkimichi, SanoShigetoshi, ImafukuShinichi, AsahinaAkihiko, KomineMayumi, EtohTakafumi, IgarashiAtsuyuki, ToriiHideshi, AbeMasatoshi, NakagawaHidemi, WatanabeAkira, YotsuyanagiHiroshi, OhtsukiMamitaro,

Psoriasis Treatment

This guidance for dermatologists focuses on the selection of appropriate biologic therapies for psoriatic patients in Japan. It considers key factors including drug effects, safety, convenience, and cost, to assist physicians in making informed decisions about biologic therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Practice GuidelineGuidelines and recommendations for the diagnosis and treatment of specific medical conditions in medical practice.

Language : English

8.

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Author: LetkoErik, YehSteven, FosterC Stephen, PleyerUwe, BrigellMitchell, GrosskreutzCynthia L,

Uveitis treatment

This study compared the efficacy and safety of different IV and SC doses of secukinumab in patients with noninfectious uveitis.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.

Author: KondaSasank, ShettyNayha, FriedmanBen, VeenstraJesse

Drug hypersensitivity

A woman in her 30s experienced a psoriasiform drug hypersensitivity reaction after receiving her second injection of secukinumab, which was initiated for hidradenitis suppurativa. This case report highlights the clinical course, histopathological correlation, and treatment of this rare reaction to secukinumab.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Author: MeasePhilip J, McInnesIain B, KirkhamBruce, KavanaughArthur, RahmanProton, van der HeijdeDésirée, LandewéRobert, NashPeter, PricopLuminita, YuanJiacheng, RichardsHanno B, MpofuShephard,

Improved psoriatic arthritis
Infections
Myocardial infarction
Stroke

Secukinumab was more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as a therapeutic target. The ACR20 response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%). Infections, including candida, were more common in the secukinumab groups than in the placebo group.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency-related ichthyosis in a child.

Author: YogarajahJ, GouveiaC, IypeJ, HäfligerS, SchallerA, NuofferJ M, FuxM, GautschiM

ARCI treatment

Patients with severe autosomal recessive congenital ichthyosis (ARCI) experience a heightened inflammatory response. This study suggests that secukinumab, an IL-17A inhibitor, could potentially be effective in treating ARCI due to its efficacy in psoriasis, which shares a similar inflammatory profile.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

15.

Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.

Author: TlustochowiczWitold, RahmanProton, SerioloBruno, KrammerGerhard, PorterBrian, WidmerAlbert, RichardsHanno B

Reduced RA activity
Infections

Secukinumab demonstrated improved efficacy in reducing disease activity over placebo as measured by DAS28 and other secondary endpoints.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis.

Author: PhanCéline, BenetonNathalie, DelaunayJuliette, ReguiaiZiad, BoulardClaire, FougerousseAnne-Claire, CinottiElisa, RomanelliMarco, Mery-BossardLaure, Thomas-BeaulieuDomitille, ParierJosiane, MaccariFrançois, PerrotJean-Luc, Ruer-MulardMireille, BastienMarie, BegonEdouard, SamimiMahtab, JacobzoneCaroline, Quiles-TsimaratosNathalie, DescampsVincent, SteffMaud, BilanPaul, Vermersch-LanglinAnnie, KemulaMathilde, AmazanEmmanuelle, Kupfer-BessaguetIngrid, CottencinAnne-Caroline, PrignanoFrancesca, LivideanuBulai, GottliebJeremy, BeauchetAlain, MahéEmmanuel,

Good tolerance
Psoriasis treatment
Adverse events
Primary failures
Relapses

Anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in elderly patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

17.

Flare-up of generalized pustular psoriasis combined with systemic capillary leak syndrome after coronavirus disease 2019 mRNA vaccination.

Author: YatsuzukaKazuki, MurakamiMasamoto, KurooYuta, FukuiMaiko, YoshidaSatoshi, MutoJun, ShiraishiKen, SayamaKoji

Rapid response to treatment
Flare-up
Systemic capillary leak syndrome

This case report describes a 65-year-old man with generalized pustular psoriasis (GPP) who experienced a flare-up after receiving his second COVID-19 mRNA vaccination. The flare-up was accompanied by systemic capillary leak syndrome (SCLS) and responded to treatment with secukinumab and corticosteroids. This is the first reported case of GPP flare-up with SCLS following COVID-19 vaccination, providing insights into potential vaccine-induced dermatological reactions.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

18.

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Author: PappK A, LangleyR G, SigurgeirssonB, AbeM, BakerD R, KonnoP, HaemmerleS, ThurstonH J, PapavassilisC, RichardsH B

Improved psoriasis treatment
Long-term safety concerns

Current treatments for psoriasis, including medications and biologics, have limitations in effectiveness or long-term safety. IL-17A, a molecule involved in inflammation, plays a key role in psoriasis. Targeting IL-17A with new therapies could offer a potential treatment approach.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real-world retrospective study and literature review.

Author: ChengPai-Shan, HouPing-Chen, YangChao-Chun, ChuChia-Bao

This study examined the response of different body regions to biologic treatments for psoriasis. The results indicate that the lower limbs are generally more resistant to treatment with ustekinumab and secukinumab compared to the upper limbs and head/neck regions.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.